July 6, 2017 10:31 AM EDT

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

John Carroll

Editor & Founder

Oxford BioMedica has scored a major supply contract with Novartis for the lentiviral vectors the pharma giant uses in its CAR-T drugs, including the industry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

A look at biotech's year of the megaround

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Neumora's major depression drug flunks first of three Phase 3 trials

No­var­tis turns to Ox­ford Bio­Med­ica for a ma­jor CAR-T sup­ply deal

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

A look at biotech's year of the megaround

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Neumora's major depression drug flunks first of three Phase 3 trials